Suppr超能文献

半乳糖呼气试验可区分变异型和严重型1-磷酸半乳糖尿苷转移酶基因型。

Galactose breath testing distinguishes variant and severe galactose-1-phosphate uridyltransferase genotypes.

作者信息

Berry G T, Singh R H, Mazur A T, Guerrero N, Kennedy M J, Chen J, Reynolds R, Palmieri M J, Klein P D, Segal S, Elsas L J

机构信息

Department of Pediatrics, University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia, 19104, USA.

出版信息

Pediatr Res. 2000 Sep;48(3):323-8. doi: 10.1203/00006450-200009000-00010.

Abstract

A galactose breath test that quantitates [1-(13)C]galactose conversion to 13CO2 provides information on the whole body galactose oxidative capacity. As there is little information on the relationship between whole body oxidation and the genotype in patients with galactosemia, we measured the 13CO2 excretion for 2 h after administration of [1-(13)C]galactose in 37 patients (3-48 y old) with galactose-1-phosphate uridyltransferase (GALT) deficiency and 20 control subjects (3-37 y old). Eleven patients with the common Q188R/Q188R genotype and no detectable erythrocyte GALT activity eliminated <2% of a bolus of [1-(13)C]galactose as 13CO2 compared with 8.47 to 28.23% in controls. This defines a severe metabolic phenotype. Seven patients with one Q188R allele and a second mutant allele such as L195P, E308K, V151A, M142K, or Q344K and one patient with a K285N/unknown genotype also released <2% as 13CO2 in 2 h. The presence of N314D or S135L as the second mutant allele does not impair total body galactose oxidation, as individuals with the GALT genotype of Q188R/N314D, K285N/N314D, and Q188R/S135L had normal 2-h galactose breath tests. Subjects with S135L/S135L, N314D/N314D, S135L/deltaT2359 as well as other rarer genotypes such as R258C/Y209C, E203K/IVSC-N314D, K285N/T138M, Q188R/D113N, S135L/F171S, R148W/N314D, and IVSC-N314D/N314D oxidized galactose comparable to controls. The dissociation of residual erythrocyte GALT activity and whole body galactose oxidative capacity is exemplified by blacks with a S135L/S135L genotype and absent erythrocyte GALT activity. An oral 2-h [1-(13)C]galactose breath test distinguishes severe and variant GALT genotypes and enables delineation of the extent of impaired galactose metabolism in an array of patients who possess diverse GALT mutations. It may prove to be useful in establishing whether a patient is capable of manifesting disease similar to patients with a Q188R/Q188R genotype.

摘要

定量检测[1-(13)C]半乳糖转化为13CO2的半乳糖呼气试验可提供关于全身半乳糖氧化能力的信息。由于关于半乳糖血症患者全身氧化与基因型之间关系的信息较少,我们测量了37例(3 - 48岁)1-磷酸半乳糖尿苷转移酶(GALT)缺乏患者和20例对照受试者(3 - 37岁)在给予[1-(13)C]半乳糖后2小时的13CO2排泄情况。11例具有常见Q188R/Q188R基因型且未检测到红细胞GALT活性的患者,作为13CO2排出的[1-(13)C]半乳糖 bolus 量小于2%,而对照组为8.47%至28.23%。这定义了一种严重的代谢表型。7例具有一个Q188R等位基因和第二个突变等位基因(如L195P、E308K、V151A、M142K或Q344K)的患者以及1例具有K285N/未知基因型的患者在2小时内作为13CO2排出的量也小于2%。作为第二个突变等位基因的N314D或S135L的存在并不损害全身半乳糖氧化,因为具有Q188R/N314D、K285N/N314D和Q188R/S135L GALT基因型的个体2小时半乳糖呼气试验正常。具有S135L/S135L、N314D/N314D、S135L/deltaT2359以及其他罕见基因型(如R258C/Y209C、E203K/IVSC - N314D、K285N/T138M、Q188R/D113N、S135L/F171S、R148W/N314D和IVSC - N314D/N314D)的受试者氧化半乳糖的情况与对照组相当。具有S135L/S135L基因型且无红细胞GALT活性的黑人体现了残余红细胞GALT活性与全身半乳糖氧化能力的分离。口服2小时的[1-(13)C]半乳糖呼气试验可区分严重和变异的GALT基因型,并能够描绘出一系列具有不同GALT突变的患者中半乳糖代谢受损的程度。它可能被证明有助于确定患者是否能够表现出与Q188R/Q188R基因型患者相似的疾病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验